Vabicaserin is a potent 5-HT 2C agonist that is currently being developed for the treatment of the psychotic symptoms of schizophrenia. In this study, in vitro and in vivo metabolism of vabicaserin was evaluated in mice, rats, dogs, monkeys and humans, and the structures of the metabolites were characterized by LC/MS and NMR spectroscopy. Vabicaserin underwent three major metabolic pathways in vitro: NADPH-dependent hydroxylation, NADPH-independent imine formation and carbamoyl glucuronidation. Following a single oral dose, vabicaserin was extensively metabolized in animals and humans, and its metabolites were mainly excreted via the urine in mice and rats. Along with the metabolites observed in vitro, secondary metabolism via oxidation and conjugation of the primary metabolites generated from the above mentioned three pathways yielded a number of additional metabolites in vivo. Carbamoyl glucuronidation was the major metabolic pathway in humans, but a minor pathway in rats. Although carbamoyl glucuronidation was a major metabolic pathway in mice, dogs and monkeys, oxidative metabolism was also extensive in these species. Hydroxylation occurred in all species, although different regional selectivity was apparent. The imine pathway also appeared to be common to several species, since vabicaserin imine was observed in humans and hydroxyl imine metabolites were observed in mice, rats and dogs. A nitrone metabolite of vabicaserin was observed in dogs and humans but not in other species. In conclusion, the major metabolic pathways for vabicaserin in humans and non-clinical safety species include carbamoyl glucuronidation, hydroxylation, formation of an imine and a nitrone.
Introduction
Recent studies have demonstrated that 5-HT 2C agonists decrease levels of dopamine in the prefrontal cortex and nucleus accumbens, brain regions that are thought to mediate the critical effects of antipsychotic drugs (Millan et al., 1998; DiMatteo et al., 1999; DiGiovanni et al., 2000) . In contrast, 5-HT 2C agonists do not decrease dopamine levels in the striatum, the brain region most closely associated with extrapyramidal side effects (Millan et al., 1998; DiMatteo et al., 1999) . In addition, a recent study demonstrated that 5-HT 2C agonists decrease firing in the ventral tegmental area but not in the substantia nigra (DiMatteo et al., 1999; DiGiovanni et al., 2000) . The differential effects of 5-HT 2C agonists in the mesolimbic pathway relative to the nigrostriatal pathway suggests that 5-HT 2C agonists have the potential to treat psychotic symptoms with lower liability for the extrapyramidal side effects associated with typical antipsychotics.
Vabicaserin is a potent 5-HT 2C full agonist and demonstrates in vitro functional selectivity for 5-HT 2C over 5-HT 2A and 5-HT 2B receptors . Vabicaserin is effective in several animal models that are predictive of antipsychotic activity, with an atypical antipsychotic profile (Marquis et al., 2006) . Administration of vabicaserin decreases nucleus accumbens dopamine levels without affecting striatal dopamine, which is indicative of mesolimbic selectivity. This profile is consistent with potential efficacy in the treatment of the psychotic symptoms of schizophrenia with decreased liability for extrapyramidal side effects. In addition, chronic administration of vabicaserin significantly decreases the number of spontaneously active mesocorticolimbic dopamine neurons, without affecting nigrostriatal dopamine neurons, consistent with the effects of atypical antipsychotics.
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This article has not been copyedited and formatted. The final version may differ from this version. Formation of a carbamoyl glucuronide (CG) was the major metabolic pathway in human liver microsomes with bicarbonate buffer and a CO 2 -enriched environment in the presence of both NADPH and UDPGA (Tong et al., 2010) . Following a single oral dose to healthy human volunteers, the carbamoyl glucuronide (CG) was the predominant metabolite in human plasma and urine, with average CG-to-vabicaserin concentration ratios ranging from 8 to 74 in plasma and 96 to 537 in urine (Tong et al., 2010) . However, oxidative metabolism also appeared to be occurring in vitro in liver microsomes (Tong et al., 2010) . Although, the in vivo formation of oxidative metabolites was evident from their presence in plasma and urine, the structures of those metabolites were previously not established due to limited availability of human biological samples (Tong et al., 2010) . Therefore, the purpose of the current study was to generate and isolate sufficient amounts of these oxidative metabolites, elucidate the structures of the major vabicaserin metabolites by LC/MS and NMR spectroscopy, determine mass balance in the safety species and compare in vitro and in vivo metabolite profiles of vabicaserin in humans and nonclinical safety species.
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Materials and Methods

Materials. [
14 C]Vabicaserin hydrochloride {(9aR, 12aS)-4, 5, 6, 7, 9, 9a, 10, 11, 12, 12a- (Phillipsburg, NJ).
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In Vivo Metabolism
For metabolism studies in male mice, rats and dogs, radio-labeled doses were used. Male CD-1 mice and Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA). The dose vehicle for mice and rats contained 2% (w/w) Tween 80 and 0.5% methylcellulose in water. Twenty (five/time point) non-fasted male mice weighing from 28 to 34 grams at the time of dosing were given a single 50 mg/kg (~300 μCi/kg) dose of vabicaserin at a volume of 20 mL/kg via intragastric gavage. Mice were kept in metabolic cages in groups of five. Twelve (three/time point) non-fasted male rats weighing from approximately 320 to 350 grams at the time of dosing were given a single 5 mg/kg (~300 μCi/kg) dose of vabicaserin at a volume of 2.5 mL/kg via intragastric gavage. Rats were kept individually in metabolism cages. Dog plasma, urine and feces for metabolite profiling were collected from the same animals used in the excretion study described earlier.
Four male cynomolgus monkeys, weighing from approximately 5 to 10 kg at the time of dosing,
were from an in-house colony. Non-fasted monkeys were given a single 25 mg/kg dose of nonradiolabeled vabicaserin at a volume of 2 mL/kg via intragastric gavage. The vehicle was the same as used in mice and rats. Animals were housed individually in metabolic cages.
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Radioactivity Determination for Mouse, Rat and Dog Studies. Plasma (10 μL) and urine (100 μL) aliquots were analyzed for radioactivity concentrations. Each urine sample was mixed
Sample Preparation for Metabolite Profiling and Metabolite Identification. Plasma samples
were pooled by mixing an equal volume from each animal for each time point, and processed as previously described (Tong et al., 2010) . Briefly, aliquots of pooled plasma were mixed with two volumes of methanol, placed on ice for about 5 min and then centrifuged. The supernatant was transferred to a clean tube and evaporated at 22°C under nitrogen in a TurboVap LV (Caliper Life Sciences) to a volume of about 0.3 mL. The concentrated extracts were centrifuged, the supernatant volumes measured, and duplicate 10 μL aliquots analyzed by LSC for extraction efficiency. Extraction efficiency was determined by comparing the total radioactivity in the extracts versus that in the samples prior to extraction. An average of greater than 80% of the plasma radioactivity was recovered in the extracts. The 24 h plasma samples from mice, rats and dogs were not analyzed due to low radioactivity concentration. Urine
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Pooled urine samples were analyzed without further preparation.
Fecal homogenates were pooled proportionally to their weight to give 0-24 h samples for mouse, rat and dog. Aliquots of 1 g of the pooled fecal homogenate were mixed with 2 mL methanol, placed on ice for about 10 min and centrifuged. The supernatant was transferred to a clean tube.
The residue was extracted three times with 2 mL of a water:methanol (3:7) mixture. The supernatants from each sample were combined, evaporated to about 1 mL, and centrifuged.
Extraction efficiency was determined by analyzing aliquots of 10 μL of the supernatant, by comparing the total radioactivity in the extracts versus the total radioactivity in the samples prior to extraction. An average of greater than 70% of the fecal radioactivity was extracted. Monkey and human fecal samples were not analyzed.
Aliquots of urine and extracts of plasma and fecal samples were analyzed by HPLC with radioactivity detection described below for metabolite profiles and by LC/MS for metabolite characterization.
High Performance Liquid Chromatography (HPLC). A Waters model 2695 HPLC system
(Waters Corp., Milford, MA) with a built-in autosampler was used for metabolite isolation and analysis for metabolite profiles. Separations were accomplished on a Luna C18(2) column (150 x 2.0 mm, 5 μm) (Phenomenex, Torrance, CA) coupled with a guard (4 x 2 mm) cartridge.
The sample chamber of the autosampler was maintained at 4°C, while the column was at an ambient temperature of about 20°C. Radioactivity chromatograms were recorded as described above. The mobile phase consisted of 10 mM ammonium acetate, pH 4.5 (A) and methanol (B) and was delivered at 0.2 mL/min. The linear gradients used are listed in Table 2 for each study.
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For other radioactive animal samples and in vitro incubations, a Flo-One β Model A525 radioactivity detector with a 250 μL flow cell was used for data acquisition. The flow rate of Ultima Flow M scintillation fluid was 1 mL/min, providing a mixing ratio of scintillation cocktail to mobile phase of 5:1.
Liquid Chromatography/Mass Spectrometry (LC/MS).
For metabolite characterization, the HPLC conditions were the same as described above, except that Agilent model 1100 (Agilent Technologies, Palo Alto, CA), Waters 2695 and Acquity UPLC (Waters) liquid chromatography systems were used. UV spectra were recorded with diode array UV detectors for all analyses.
Most of the LC/MS analyses were conducted with mobile phase Gradient C (Table 2) . Mass spectral data for vabicaserin and its metabolites were obtained with LCQ ion trap (Thermo, San Jose, CA), quadrupole time-of-flight (Q-TOF) (Waters) and triple quadrupole (Waters) mass spectrometers. Each mass spectrometer was equipped with an electrospray ionization source and operated in the positive ionization mode. Settings for each mass spectrometer were optimized to provide a structurally relevant range of product ions from MS/MS and MS n experiments.
Product ion spectra recorded with the triple quadrupole mass spectrometer employing a collision energy setting of 22 eV were used as the reference spectra to confirm metabolite identifications.
MassLynx (versions 3.5, 4.0, and 4.1, Waters) and Xcalibur (version 1.3, Thermo) software were used for collection and analysis of LC/MS data.
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The proton spectra were acquired with 32,768 data points over a 6,602 Hz spectral window using a 30º pulse and standard pulse sequence. Data were Fourier transformed with a 0. 
This article has not been copyedited and formatted. The final version may differ from this version. Figure 3 . Although quantitative differences among the various species investigated were apparent, the in vitro metabolite profiles of vabicaserin were qualitatively similar across the species (Figures 2 and 3) , and all human metabolites were detected in one or more animal species. Monkey liver microsomes generated similar profiles to those of humans, except that P2 was detected in relatively higher intensity, while P6 was observed in relatively lower intensity than in human liver microsomes. However, as the purpose of the in vitro study was to generate metabolites for structural elucidation and for qualitative profiling, the in vitro incubation conditions were not optimized for each species to provide in vitro and in vivo extrapolation.
Excretion
Mice: Excretion of radioactivity was determined in the samples collected up to 24 h following oral administration of 50 mg/kg [ 14 C]vabicaserin to male CD-1 mice in the metabolism study.
Urine was the major route of excretion, with 59.6% of the radioactive dose recovered in the 24 h post-dose. Fecal elimination in the first 24 h post-dose accounted for 13.6% of the dosed radioactivity.
Rats: The excretion of radioactivity in male Sprague-Dawley rats was evaluated after a single oral (gavage) dosage of 5 mg/kg [ 14 C]vabicaserin. The total recovery of radioactivity (feces, urine, and cage rinse) over a period of 5 days (120 h) was 93.8%. The major route of excretion of radioactivity was the urine (64.3%); fecal excretion was relatively minor (28.0%). The rate of excretion of radioactivity was rapid, with 87.4% of the oral dose recovered in urine and feces (including cage rinse) in the first 24 h after dosing.
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Excretion of radioactivity in rats was rapid, with the majority of the radioactivity recovered in the first 24 h post-dosing. These results were consistent with the finding in the mass balance study, where 64% of the administered radioactivity was recovered in urine.
Dogs: The excretion of radioactivity in male beagle dogs was evaluated after a single oral Table 5 . Percentages of vabicaserin and its metabolites in urine of various species as determined by their chromatographic distribution are summarized in Table 6 .
In mice, vabicaserin, CG and hydroxyl vabicaserin (P2 and P3) were the major radioactive components in plasma (Figure 4 In rats, vabicaserin was extensively metabolized to predominantly oxidative metabolites.
Unchanged vabicaserin represented ≤ 20% of the total radioactivity in plasma and < 1% of the administered radioactive dose in urine. Hydroxyl vabicaserin (P1, P2 and P3) and keto vabicaserin (P7) were the major drug-related components in rat plasma ( Figure 5 ). The hydroxyl metabolites (P1 and P3), keto vabicaserin (P7), and the glucuronide (P9) were the major metabolites in urine. CG was not detected in rat plasma or urine. Metabolites P3, P8, P10, and P11 and only trace amounts of vabicaserin were detected in rat feces.
In the biliary excretion and metabolite profile study in rats, vabicaserin represented an average of < 3% of radioactivity in bile, and 3% to 4% of radioactivity in urine. Vabicaserin and its metabolites were excreted in bile almost solely as conjugates. Biliary metabolite profiles did not change significantly over time. The major biliary metabolites included CG, hydroxyl vabicaserin
This article has not been copyedited and formatted. The final version may differ from this version. of the radioactivity in bile. Urinary metabolites included hydroxyl vabicaserin (P1, P2, P3, and P4), keto vabicaserin (P7), hydroxyl vabicaserin imine sulfate (P8), hydroxyl vabicaserin sulfate (P10), hydroxyl vabicaserin glucuronide (P9), and N-acetyl hydroxyl vabicaserin (P12).
In dogs, vabicaserin was extensively metabolized after administration of an enteric-coated capsule containing [ 14 C]vabicaserin. Oxidative metabolism was the major metabolic pathway, while formation of CG was also observed. Vabicaserin represented < 21% of the radioactivity in plasma and no more than 0.5% of the administered radioactive dose in urine, similar to mice and rats. In dog plasma, vabicaserin, CG, P1, P2, P3 as well as hydroxyl vabicaserin imine (P13)
were the major drug-related components. Metabolites observed in dog plasma were also detected in dog urine. A hydroxyl vabicaserin sulfate (P17) and a diazepinyl vabicaserin carboxylic acid (P18), which was not detected in plasma, were observed in urine. Hydroxyl vabicaserin metabolites (P2, P3, and P20), a keto vabicaserin (P7), and a hydroxyl vabicaserin imine (M15) were detected in fecal extracts. Some metabolites of vabicaserin differed in dogs compared with those in rats. Sulfate metabolites were less abundant in dogs, and CG was detected in dogs but not in rats.
Representative summed mass chromatograms of plasma and urine samples obtained from monkeys and humans following oral administration vabicaserin are shown in Figures 7 and 8 .
Non-labeled material was administered to monkeys and humans, and oxidative metabolites were not quantified in these samples. In monkeys, vabicaserin was extensively metabolized via both phase I and II metabolism. In monkey plasma, along with the metabolites observed in the in
This article has not been copyedited and formatted. The final version may differ from this version. After oral (capsule) administration of vabicaserin to humans, vabicaserin was extensively metabolized, primarily to the carbamoyl glucuronide (CG). Vabicaserin nitrone (P5) was observed in humans, as seen in dog plasma (Figures 6 and 8) . Generally, urinary metabolite profiles were similar to plasma profiles (Figures 7-8) . A number of metabolites, which were not detected in in vitro incubations, were observed in plasma and/or urine of humans and animal species examined. These were the secondary metabolite formed through oxidative metabolism and conjugation of the primary metabolites of hydroxylation, imine formation or carbamoyl glucuronidation.
Discussion
The present study indicated that vabicaserin undergoes NADPH-dependent oxidative metabolism to form hydroxyl metabolites (P1-P4), NADPH-independent formation of an imine (P6) as well as UGT-catalyzed formation of a carbamoyl glucuronide (CG) in a CO 2 enriched environment in human liver preparations (Figure 9 ). Vabicaserin nitrone (P5) was generated directly from vabicaserin or from P6 in human liver microsomes in the presence of NADPH.
Radioactivity was eliminated rapidly in mice (73.2% in 24 h), rats (87.4% in 24 h) and dogs (84.2% in 48 h) following oral administration of [ 14 C]vabicaserin. Urine was the major route of elimination of the dosed radioactivity following oral administration of [ 14 C]vabicaserin to mice and rats, while fecal elimination was the major route of excretion in dogs. Since nonradiolabeled vabicaserin was administered to monkeys and humans, excretion of total drug derived materials could not be determined. However, quantitative data obtained by LC/MS analysis indicated that less than 1% of the oral dose was eliminated as unchanged drug and >50% of the administered dose was excreted as CG in urine of humans (Tong et al 2010) .
Vabicaserin was extensively metabolized in all species and species differences were observed following a single oral dose to humans and animals. Although a number of additional metabolites were observed, in vivo metabolism of vabicaserin generally followed the same metabolic pathways observed in vitro: hydroxylation, imine formation and carbamoyl glucuronidation. Further metabolism of the primary metabolites through oxidative metabolism and conjugation yielded additional metabolites. As previously discussed (Tong et al., 2010) , carbamoyl glucuronidation was the major metabolic pathway in humans, but a minor metabolic pathway in rats. Carbamoyl glucuronidation was also a major metabolic pathway in mice, dogs
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Hydroxylation reactions occurred in all species, although different regional selectivity seemed to exist. Although vabicaserin imine was observed only in humans, secondary metabolites of the imine were observed in all species except monkey, suggesting that this metabolic pathway also exists in mice, rats and dogs. Vabicaserin nitrone (P5) was observed in dogs and humans but not in the other species studied.
Vabicaserin is composed of a fused four-ring system, including benzene, diazepane, piperidine, and cyclopentane rings. 
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